Bharat Biotech’s Covaxin gets SEC nod for use in children aged 2-18 years, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The decision comes after a thorough review of Bharat Biotech’s submitted data from clinical trials in the 2-18 years age group for COVAXIN (BBV152) to Central Drugs Standard Control Organisation (CDSCO), The decision comes after a thorough review of Bharat Biotech’s submitted data from clinical trials in the 2-18 years age group for COVAXIN (BBV152) to Central Drugs Standard Control Organisation (CDSCO), , Read More